Predictive Factors for Incidental Contralateral Carcinoma in Patients with Unilateral Micropapillary Thyroid Carcinoma

Jung Eun Huh, Sang Soo Kim1, Ji Hyun Kang1, Bo Gwang Choi1, Byung Joo Lee1, Jin Choon Lee5, Yun Kyung Jeon1, Bo Hyun Kim1, Soo Geun Wang2, Yong Ki Kim3, In Joo Kim1

Department of Internal Medicine, BHS Hanseo Hospital, Busan; Departments of Internal Medicine1 and Otolaryngology2, Pusan National University Hospital, Busan; Kim Yong Ki Internal Medicine Clinic3, Busan, Korea

Background: Whether thyroid lobectomy alone is a sufficient treatment for papillary thyroid microcarcinoma (PTMC) remains controversial. The aim of this study is to evaluate the predictive factors for incidental contralateral carcinoma in patients confirmed of unilateral PTMC preoperatively.

Methods: Between January 2007 and December 2009, 393 patients underwent thyroid surgery for unifocal and unilateral PTMC preoperatively at Pusan National University Hospital. A total thyroidectomy with central neck dissection was routinely performed for these patients during this study period.

Results: Among the 393 cases in the cohort, 77 patients (19.6%) had incidental PTMC in the contralateral lobe. In patients with incidental contralateral carcinoma, there was higher prevalence in extrathyroid extension, occult ipsilateral carcinoma, pathologic Hashimoto’s thyroiditis, and central lymph node metastasis compared to those without contralateral carcinoma. The mean tumor size also increased in patients with contralateral carcinoma. Multivariate logistic regression showed that extrathyroid extension (P = 0.049), occult ipsilateral carcinoma (P < 0.001), pathologic Hashimoto’s thyroiditis (P = 0.038), and central lymph node metastasis (P = 0.002) were predictive factors for incidental contralateral carcinoma.

Conclusion: In conclusion, multifocality in the ipsilateral lobe, central lymph node metastasis, extrathyroid extension, and Hashimoto’s thyroiditis is associated with the presence of contralateral carcinoma. Thus, if these factors are found by preoperative and/or postoperative evaluation, total thyroidectomy or completion thyroidectomy is necessary for the treatment of PTMC. (Endocrinol Metab 27:194-199, 2012)

Key Words: Bilateral, Hashimoto disease, Incidental finding, Papillary thyroid carcinoma, Thyroidectomy

INTRODUCTION

Papillary thyroid microcarcinoma (PTMC), as a specific subtype of papillary thyroid carcinoma (PTC), which is defined by the World Health Organization as a papillary carcinoma measured at 10 mm or less in its maximal diameter [1]. Recently, technological improvement and widespread use of ultrasonography (US) has helped to identify smaller nodule and routine US-guided fine needle aspiration biopsy (FNAB) for this nodule has facilitated the diagnosis of PTMC. So the incidence of PTMC has increased rapidly [2,3]. PTMC is usually slowly growing and has an excellent prognosis [4,5], so conservative treatment such as unilateral lobectomy has been advocated for some patients with these tumors. However locoregional recurrence has been reported in these patients [6,7] and rare cases distant metastasis have also reported [8].

So the management of PTMC remains controversial [9,10]. Recent consensus guidelines by American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer [11] recommend that lobectomy alone may be sufficient treatment for small (< 1 cm), low-risk, unifocal, and intrathyroidal papillary carcinoma. They classify low risk lesions as those with no lymphovascular invasion or no evidence of more aggressive

Copyright © 2012 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cellular variants on histologic studies. This recommendation is based, among other considerations, on the risk of contralateral disease [12]. In these patients with PTMC treated by lobectomy, completion thyroidectomy is considered if the risk of PTC in the contralateral lobe was substantial.

The aim of this study was to evaluate any possible predictive factors for incidental contralateral carcinoma in patients confirmed of unifocal and unilateral PTMC preoperatively, then to find out the perioperative factors we could recommend to undergo total thyroidectomy rather than lobectomy in the patients with PTMC.

MATERIALS AND METHODS

1. Patients

Between January 2007 and December 2009, 428 patients underwent thyroid surgery for unilateral PTMC, confirmed to the unifocal and unilateral lobe and no evidence of PTC in the contralateral lobe by preoperative US or FNAB at Pusan National University Hospital. The FNAB to diagnose thyroid malignancy was mainly performed in the nodule with ultrasonographic features for suspicious thyroid malignancy such as hypoechogenicity or markedly hypoechogenicity, ill-defined margin, presence of calcification and taller than wide shape. Two surgeons had performed thyroid surgeries during this period. A bilateral central compartment neck dissection was routinely performed during the total thyroidectomy. Of the 428 patients, three patients underwent unilateral lobectomy so they were excluded. In addition, 32 patients were excluded due to following reasons: patients with other coexisting pathologic findings (n = 4); Hürthle cell adenoma (n = 2), follicular adenoma (n = 1), and follicular carcinoma (n = 1); patients with previous thyroid drug history (n = 13) or unavailable preoperative thyroid stimulating hormone (TSH) (n = 15), to establish the effect of TSH on multifocal disease of PTC. Finally 393 patients with unilateral PTMC preoperatively confirmed were available for this study. Central neck dissection was performed in 390 patients (99.2%) of the patients finally enrolled.

The TSH level was checked within 3 months before surgery and was determined by immunoradiometric assay (Coat-A-Count, TSH IRMA; Diagnostic Products Co., Los Angeles, CA, USA). The analytical sensitivities of the assay for TSH were 0.03 mIU/L and the intra-assay coefficients of variation ranged 1.9-5.8%. Normal reference ranges for TSH were 0.4-5.0 mIU/L. Pathologic Hashimoto's thyroiditis was defined as the presence of diffuse plasma and lymphocytic cell infiltration, oxyphilic cells, the formation of lymphoid follicles, and reactive germinal centers. However, a peritumor inflammatory response was not considered Hashimoto's thyroiditis. The pathologic specimens after total thyroidectomy were routinely sectioned every 3 mm and were stained with hematoxylin and eosin for histopathologic examination. Multifocal disease was defined as more than one tumor focus in the ipsilateral or contralateral lobe of the primary tumor.

Informed consent was obtained from each participant at the time of surgery. This retrospective review protocol was approved by the Institutional Review Board at Pusan National University Hospital.

2. Statistical analysis

Statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). All data are expressed as mean ± SD. Independent two-sample t-test was used to compare two independent groups. Pearson’s X² test was performed to analyze categorical data as appropriate. Factors related to incidental contralateral carcinoma were analyzed using multivariate logistic regression according to the procedure “Enter.” Multivariate model for incidental contralateral carcinoma was adjusted for age, sex, preoperative TSH level, tumor size, extrathyroid extension, lymphvascular invasion, ipsilateral multifocality, coexisting Hashimoto’s thyroiditis, and central lymph node (LN) metastasis as independent variables. Predicted probability of incidental contralateral carcinoma was assessed by logistic regression and calculated by the following formula:

Predictive probability = 1 / (1 + Exp [-a0 + a1X1 + a2X2 + a3X3 + a4X4]),

where Exp represents exponent, a0 is the intercept estimate, a1-4 is the estimate of clinicopathologic variables, and X is the point of clinicopathologic variables. The cut-off values of the point score for predicting incidental contralateral carcinoma was calculated using the receiver operating characteristics (ROC) curve. Subsequently, the sensitivity and specificity of this cut-off value were estimated. A P value of less than 0.05 was considered statistically significant.

RESULTS

1. Patient characteristics

The cohort included 53 men and 340 women with ages ranging 20-77 (mean age, 48.0 ± 10.7 years). The mean tumor size was 0.64 ± 0.23 cm in the patients with PTMC. The pathological extrathyroid extension, LN metastasis, and lymphovascular invasion was found in 44.8%, 40.7%, and 1.0% of the analyzed patients, respec-

http://dx.doi.org/10.3803/EnM.2012.27.3.194  http://www.enm-kes.org
tively. With regard to LN metastasis, central LN involvement comprised 38.9% (n = 153 of 393), whereas lateral LN involvement comprised 9.7% (n = 38 of 354) of the total patients. No subject was initially diagnosed with distant metastasis. Of the 393 cohort cases, 116 patients (29.3%) had multifocality on tissue pathology. According to the American Joint Committee on Cancer/Union Internationale Contre le Cancer pathologic tumor-node-metastasis classification, there were 218 patients with stage I (55.5%), 150 with stage III (38.2%), and 25 with stage IV disease (6.3%).

2. Clinical/pathologic characteristics according to contralateral carcinoma

The clinical and pathologic parameters of this study cohort are summarized in Table 1; the patients were divided into those with contralateral carcinoma and those without contralateral carcinoma. Seventy-seven patients (19.6%) had incidental papillary carcinoma in the contralateral lobe. Higher prevalence in extrathyroid extension, occult ipsilateral carcinoma, pathologic Hashimoto’s thyroiditis and central LN metastasis was noted compared to those without contralateral carcinoma. The mean tumor size was also increased in the patients with contralateral carcinoma (0.70 ± 0.21 vs. 0.63 ± 0.23 without contralateral carcinoma, P = 0.008). There were no differences in age, gender, preoperative TSH level and lymphovascular invasion between 2 groups.

3. Predictive factors for incidental contralateral carcinoma

Multivariate logistic regression showed that extrathyroid extension (P = 0.049), occult ipsilateral carcinoma (P < 0.001), pathologic Hashimoto’s thyroiditis and central LN metastasis were significant predictors of incidental contralateral carcinoma. The mean tumor size was also increased in the patients with contralateral carcinoma (0.70 ± 0.21 vs. 0.63 ± 0.23 without contralateral carcinoma, P = 0.008). There were no differences in age, gender, preoperative TSH level and lymphovascular invasion between 2 groups.

Table 1. Clinicopathological factors according to incidental contralateral carcinoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>Contralateral carcinoma (+) (n = 77)</th>
<th>Contralateral carcinoma (–) (n = 316)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>46.8 ± 10.5</td>
<td>48.8 ± 10.7</td>
<td>0.252</td>
</tr>
<tr>
<td>Female gender</td>
<td>68 (88.3)</td>
<td>272 (86.1)</td>
<td>0.607</td>
</tr>
<tr>
<td>TSH (mIU/L)</td>
<td>1.77 ± 1.27</td>
<td>2.01 ± 2.68</td>
<td>0.236</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>0.70 ± 0.21</td>
<td>0.63 ± 0.23</td>
<td>0.008*</td>
</tr>
<tr>
<td>Extrathyroid extension</td>
<td>44 (57.1)</td>
<td>132 (41.8)</td>
<td>0.015*</td>
</tr>
<tr>
<td>Lymphovascular invasion</td>
<td>2 (2.6)</td>
<td>2 (0.6)</td>
<td>0.175</td>
</tr>
<tr>
<td>Occult ipsilateral multifocality</td>
<td>37 (48.1)</td>
<td>39 (12.3)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Coexisting Hashimoto’s thyroiditis</td>
<td>14 (18.2)</td>
<td>26 (8.2)</td>
<td>0.010*</td>
</tr>
<tr>
<td>Central LN metastasis</td>
<td>46 (59.7)</td>
<td>107 (33.9)</td>
<td>&lt;0.001†</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD or frequency (%). P values were analyzed by independent two-sample t-test between 2 independent groups.

Table 2. Prognostic factors for incidental contralateral carcinoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>Category</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>≥ 45 vs. &lt; 45</td>
<td>0.763</td>
<td>0.319-1.823</td>
<td>0.542</td>
</tr>
<tr>
<td>Gender</td>
<td>Male vs. Female</td>
<td>0.608</td>
<td>0.330-1.119</td>
<td>0.110</td>
</tr>
<tr>
<td>TSH (mIU/L)</td>
<td>≥ 2.5 vs. &lt; 2.5</td>
<td>1.034</td>
<td>0.536-1.997</td>
<td>0.920</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>&gt; 0.5 vs. ≤ 0.5</td>
<td>0.825</td>
<td>0.433-1.573</td>
<td>0.560</td>
</tr>
<tr>
<td>Extrathyroid extension</td>
<td>Presence vs. Absence</td>
<td>1.824</td>
<td>1.002-3.248</td>
<td>0.049*</td>
</tr>
<tr>
<td>Lymphovascular invasion</td>
<td>Presence vs. Absence</td>
<td>1.682</td>
<td>0.205-13.780</td>
<td>0.628</td>
</tr>
<tr>
<td>Occult ipsilateral multifocality</td>
<td>Presence vs. Absence</td>
<td>6.635</td>
<td>3.638-12.102</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Coexisting Hashimoto’s thyroiditis</td>
<td>Presence vs. Absence</td>
<td>2.414</td>
<td>1.052-5.538</td>
<td>0.038*</td>
</tr>
<tr>
<td>Central LN metastasis</td>
<td>Presence vs. Absence</td>
<td>2.455</td>
<td>1.387-4.346</td>
<td>0.002*</td>
</tr>
</tbody>
</table>

P values were analyzed using multivariate logistic regression according to the procedure “Enter.”

Table 3. Estimate and point clinicopathological characteristics for incidental contralateral carcinoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>Characteristic</th>
<th>Point</th>
<th>Estimate</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interceptor</td>
<td></td>
<td>-2.293</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extrathyroid extension</td>
<td>Absence</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presence</td>
<td>1</td>
<td>0.590</td>
<td>0.049</td>
</tr>
<tr>
<td>Occult ipsilateral multifocality</td>
<td>Absence</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presence</td>
<td>1</td>
<td>1.892</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Coexisting Hashimoto’s thyroiditis</td>
<td>Absence</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presence</td>
<td>1</td>
<td>0.881</td>
<td>0.038</td>
</tr>
<tr>
<td>Central LN metastasis</td>
<td>Absence</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presence</td>
<td>1</td>
<td>0.898</td>
<td>0.002</td>
</tr>
</tbody>
</table>

To calculate the predicted probability of incidental contralateral carcinoma, the estimate and P value were estimated with 4 clinicopathological variables selected by multiple logistic regression analysis. LN, lymph node.
Hashimoto’s thyroiditis ($P = 0.038$), and central LN metastasis ($P = 0.002$) were predictive for the incidental contralateral carcinoma (Table 2). Age, gender, size, and lymphovascular invasion were not associated with the presence of incidental carcinoma in contralateral lobe. Four clinicopathological parameters (extrathyroid extension, occult ipsilateral multifocality, coexisting Hashimoto’s thyroiditis, and central LN metastasis), selected by logistic regression analysis, were used to evaluate the risk of incidental contralateral carcinoma and the estimate and point of each characteristic are shown in Table 3. We constructed ROC curves using these data (Fig. 1). The integrated ROC curve expressed an important sensitivity (67.5%), specificity (73.1%), and area under the curve (0.759). The predictive probability of incidental contralateral metastasis at this point was 0.31.

**DISCUSSION**

In this study, the operation method such as total thyroidectomy and central neck dissection were routinely performed in the same manner in most PTMC during study period. Throughout the homogenous study patients, we could derive the result that patients who had multifocal tumor in the ipsilateral lobe, coexisting Hashimoto’s thyroiditis, extrathyroid extension of primary tumor and central LN metastasis have the possibility of having additional contralateral cancer.

The reported rates of contralateral PTC discovered in completion thyroidectomy or total thyroidectomy specimens ranges 13-56% [13,14]. For PTMC, up to 40% of patients have been reported to have contralateral carcinoma at the time of histological review, but these incidence show a considerable difference according to study population [14,15]. In our results, 19.6% of PTMC had contralateral carcinoma and this incidence is consistent with previous study restricted to those with preoperatively unilateral confined PTMC [16].

Multifocality is defined as more than one cancerous lesion can be located in the ipsilateral lobe only. Some previous studies reported similar findings to our study that ipsilateral multifocal disease was the predictive factor for contralateral cancer in PTMC [16]. But the relation between multifocality and LN metastasis or recurrence is controversial. Several studies reported that multifocal disease was significant factors for recurrence in PTC [15]. But other studies reported that there was no significant association between multifocality and LN metastasis or recurrence [17]. One explanation for this observation is that multifocality most often is the result of the development of multiple independent tumors and not a manifestation of intraglandular dissemination, as demonstrated by recent molecular investigations of multifocal PTC [17-20]. Each of the different microtumors seems to have the limited growth potential. But to evaluate the prognostic effect of multifocality, it is considered that the other further long-term studies may be necessary.

In the previous reports, other multiple factors have been shown to predict the contralateral cancer. Positive LN metastasis at the initial operation had been associated with PTC in remaining lobe [21, 22]. In addition, the infiltrations of thyroid capsule have been linked to bilateral PTC [22]. But these reported were conducted from PTC. Our results for PTMC are consistent with these reports, and extrathyroid extension and central LN metastasis are predictive factors for contralateral cancer. In addition, the strengths of this study different from similar studies are that this study had more large number of patients. The operations were performed in the same manner such as routine total thyroidectomy and central LN dissection during short term period. Thus, more accurate prevalence of incidental contralateral carcinoma could be achieved and more reliable results were acquired regarding the predictive factors for contralateral tumors.

Interestingly, in our study the presence of Hashimoto’s thyroiditis was also a significant predictive factor for the presence of contralateral PTC. Patients with Hashimoto’s thyroiditis are believed to be at higher risk for PTC compared with patients without Hashimoto’s thyroiditis [23]. A few previous reports have shown that the cases
of PTC coexisted with Hashimoto’s thyroiditis are more multicentric than those without Hashimoto’s thyroiditis [24]. And Kim et al. [25] reported that multifocality and bilaterality are more frequent with the coexistence of Hashimoto’s thyroiditis and PTC including PTMC, consistent with our results. The pathogenesis and the prognosis of the coexistence of PTC and Hashimoto’s thyroiditis remain controversial. But Hashimoto’s thyroiditis might represent the host immune response to preexisting PTC; PTC might be induced or triggered by preexisting Hashimoto’s thyroiditis, and a common mechanism, such as imbalance between apoptotic/antiapoptotic pathways, may be involved in the two diseases [26]. Previous studies have reported that chronic inflammation responses such as those associated with autoimmune thyroiditis might act as carcinogens [27] or rearranged in transformation/PTC oncogene that is known to be highly specific to PTC might be expressed in Hashimoto’s thyroiditis [28]. Chronic inflammatory change may occur in the whole thyroid gland with multifocal foci, so increase the incidence of multifocality and contralateral cancer.

In this study, the scores of each clinical variable for predicted probability of contralateral carcinoma were selected by logistic regression analysis. Findings suggesting absence of contralateral carcinoma were scored as 0, while those indicating contralateral carcinoma were scored as 1. Using this scoring system from perioperative evaluation, total thyroidectomy or completion thyroidectomy has high scoring point, although this score system exhibited relatively fair diagnostic accuracy.

The limitations of this study are that it was not based on longitudinal observations but was conducted with a cross-sectional design. Moreover, even though multifocality in the ipsilateral lobe, coexisting Hashimoto’s thyroiditis, extrathyroid extension of primary tumor and central LN metastasis have the possibility of having additional contralateral cancer, its effect in the overall prognostic factors such as tumor recurrence and survival has not yet been determined. The second, the predictive factors associated with incidental contralateral carcinoma in this study could be detected retrospectively after ipsilateral lobectomy and central neck dissection. Thus, it is considered to have more clinically potential meaning to find out preoperatively the predictive factors related to contralateral carcinoma. The third, the patients of this study were mainly performed US to diagnose for PTC but not to reevaluate tumor staging preoperatively. Thus, we cannot assess which preoperative US characteristics incidental papillary carcinoma of this study did have and cannot convince that multifocal disease of our study absolutely was incidental papillary carcinoma.

In conclusion, multifocality in the ipsilateral lobe, lymph node metastasis, extrathyroid extension, and coexisting Hashimoto’s thyroiditis is associated with the presence of incidental contralateral cancer. So, if these factors are found by perioperative and/or postoperative evaluation, total thyroidectomy or completion thyroidectomy is necessary for the treatment of PTMC.

Y. Ak

배경: 감상선 미세유두암에서 감상선 엽절체술만으로 충분하지는 여전히 논쟁의 여지가 많다. 수술 전 편측엽에 단독의 감상선 미세유두암으로 판단된 환자에서 우연성 반대엽 감상선암 병발에 대한 예측인자를 확인하고자 하였다.

방법: 2007년 1월부터 2009년 12월까지 부산대학교병원에서 수술전 단독의 일측성 감상선 미세유두암으로 판단되어 수술을 시행한 399명을 대상으로 하였다. 연구 기간 동안 모든 환자에서 감상선 전절체술과 중앙 림프절 절제술을 기본적인 수술로 시행하였다.

결과: 총 399명의 환자 중 77명(19.6%)에서 반대엽에서 우연히 감상선 유두암이 발병하였다. 반대엽 감상선 유두암이 있는 환자군에서 없는 환자군에 비해 감상선의 침범, 동측엽의 감상선암 병발, 병리학적 하시모토 감상선염, 중앙 림프절 전이가 많이 관찰되었다. 평균 중앙의 크기 또한 반대엽 감상선 유두암이 있는 환자군에서 더 컸다. 다변량 로지스틱 회귀분석에서 감상선의 침범 (P=0.049), 동 측엽 감상선암 병발 (P<0.001), 병리학적 하시모토 감상선염 (P = 0.038) 및 중앙 림프절 전이가 (P=0.002) 우연성 반대엽 감상선암 병 발에 대한 예측인자로 확인되었다.

결론: 동측엽의 다중성 병변, 림프절 전이, 감상선의 침범 및 하 시모토 감상선염 병발 등이 우연성 반대엽 감상선암의 존재와 연관이 있었다. 감상선 미세유두암에서 수술 중 또는 수술 후 이런 요소들이 확인되면 감상선 전절체술 또는 반대엽 절제술을 고려할 수 있었다.

REFERENCES

3. Leenhardt L, Grosclaude P, Cheré-Challine L; Thyroid Cancer Committee: Increased incidence of thyroid carcinoma in france: a true epidemic or thy-
Contralateral Carcinoma in PTMC

199

reported nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060, 2004


12. Grigsby PW, Reddy RM, Moley JF, Hall BL: Contralateral papillary thyroid cancer at completion thyroidecomy has no impact on recurrence or survival after radioiodine treatment. Surgery 140:1043-1047, 2006


http://dx.doi.org/10.3803/EnM.2012.27.3.194

http://www.enm-kes.org